Literature DB >> 3490610

Serum interleukin-1 (IL-1) activity in alcoholic hepatitis.

C J McClain, D A Cohen, C A Dinarello, J G Cannon, S I Shedlofsky, A M Kaplan.   

Abstract

Interleukin-1 (IL-1) is a monokine which has been demonstrated to produce a variety of seemingly diverse metabolic events including fever, neutrophilia, anorexia, altered mineral metabolism, muscle catabolism, and fibroblast proliferation. Because many of the clinical features of alcoholic hepatitis are metabolic abnormalities that have been shown to be caused by IL-1, we questioned whether patients with alcoholic hepatitis had elevated serum levels of IL-1. Six patients with alcoholic hepatitis had serum IL-1 activity measured by the thymocyte costimulator assay after serum inhibitors were removed. Their values were compared to those of 6 age and sex-matched healthy controls. Patients with alcoholic hepatitis had markedly elevated serum IL-1 activity, with the integrated value of all fractions having serum IL-1 activity being 9.8 times that of controls. IL-1 activity in serum from alcoholic hepatitis patients also was blocked by antibody to IL-1. We conclude that patients with alcoholic hepatitis have increased serum IL-1 activity which may play a role in certain of the metabolic complications of alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3490610     DOI: 10.1016/0024-3205(86)90554-0

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  18 in total

Review 1.  A Unifying Hypothesis Linking Hepatic Adaptations for Ethanol Metabolism to the Proinflammatory and Profibrotic Events of Alcoholic Liver Disease.

Authors:  Zhi Zhong; John J Lemasters
Journal:  Alcohol Clin Exp Res       Date:  2018-09-17       Impact factor: 3.455

2.  Imbalance of IL-1 beta and IL-1 receptor antagonist mRNA in liver tissue from hepatitis C virus (HCV)-related chronic hepatitis.

Authors:  L Gramantieri; A Casali; D Trerè; S Gaiani; F Piscaglia; P Chieco; B Cola; L Bolondi
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

Review 3.  Alcoholic liver disease: pathogenesis, management, and novel targets for therapy.

Authors:  Eric S Orman; Gemma Odena; Ramon Bataller
Journal:  J Gastroenterol Hepatol       Date:  2013-08       Impact factor: 4.029

Review 4.  Targeting inflammation for the treatment of alcoholic liver disease.

Authors:  Ming-Jiang Xu; Zhou Zhou; Richard Parker; Bin Gao
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

5.  Immunohistochemical detection of tumor necrosis factor-alpha, other cytokines and adhesion molecules in human livers with alcoholic hepatitis.

Authors:  W Ohlinger; H P Dinges; K Zatloukal; S Mair; F Gollowitsch; H Denk
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

6.  Is the intercellular adhesion molecule-1/leukocyte function associated antigen 1 pathway of leukocyte adhesion involved in the tissue damage of alcoholic hepatitis?

Authors:  P Burra; S G Hubscher; J Shaw; E Elias; D H Adams
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 7.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

8.  Interleukin-1beta induces macrophage inflammatory protein-1beta expression in human hepatocytes.

Authors:  Ting Zhang; Chang-Jiang Guo; Yuan Li; Steven D Douglas; Xiao-Xue Qi; Li Song; Wen-Zhe Ho
Journal:  Cell Immunol       Date:  2003-11       Impact factor: 4.868

Review 9.  Apoptosis and necrosis in the liver.

Authors:  Maria Eugenia Guicciardi; Harmeet Malhi; Justin L Mott; Gregory J Gores
Journal:  Compr Physiol       Date:  2013-04       Impact factor: 9.090

10.  Serum levels of interleukin-1 beta and interleukin-6 in patients with chronic pancreatitis.

Authors:  T Bamba; U Yoshioka; H Inoue; Y Iwasaki; S Hosoda
Journal:  J Gastroenterol       Date:  1994-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.